Copyright
©The Author(s) 2020.
World J Clin Oncol. Nov 24, 2020; 11(11): 898-917
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.898
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.898
Figure 1 Radiotherapy and immune checkpoint inhibitors: Complementary mechanisms of action.
The yellow arrows indicate anti-tumor processes and the red lines, mechanisms that block or suppress this anti-tumor immune response. APC: Adenomatous polyposis coli; ICI: Immune checkpoint inhibitors.
Figure 2 Decision making process diagram to evaluate candidate patients for durvalumab consolidation according to PACIFIC trial strategy in clinical practice.
1In Europe. CRT: Chemoradiotherapy; EBUS: Endobronchial ultrasonography; EUS: Esophageal ultrasonography; HIV: Human immunodeficiency virus; NSCLC: Non-small cell lung cancer; PET-CT: Positron emission tomography-computed tomography; PD-L1: Programmed cell death ligand 1.
- Citation: Mielgo-Rubio X, Rojo F, Mezquita-Pérez L, Casas F, Wals A, Juan M, Aguado C, Garde-Noguera J, Vicente D, Couñago F. Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World J Clin Oncol 2020; 11(11): 898-917
- URL: https://www.wjgnet.com/2218-4333/full/v11/i11/898.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i11.898